Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer:
2021
Background:Epidermal growth factor receptor-mutated (EGFR+) non-small-cell lung cancer (NSCLC) patients failing tyrosine kinase inhibitors (TKI) can benefit from next-line targeted therapies, but i...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
49
References
3
Citations
NaN
KQI